NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING LEVETIRACETAM
The present invention relates to pharmaceutical compositions comprising levetiracetam as active ingredient, the invention relates specifically to a prolonged release formulation.
1 . A pharmaceutical composition in the form of a tablet comprising 500 mg of Levetiracetam, 193.00 mg of a hydroxypropyl methylcellulose, 3.5 mg of anhydrous colloidal silica and 3.50 mg of magnesium stearate.
2 . A pharmaceutical composition in the form of a tablet comprising 500 mg of Levetiracetam, 96.50 mg of a hydroxypropyl methylcellulose, 96.50 mg of a mixture comprising polyvinylacetate and polyvinylpyrrolidinone, 3.5 mg of anhydrous colloidal silica and 3.50 mg of magnesium stearate.
3 . A pharmaceutical composition in the form of a tablet comprising 500 mg of Levetiracetam, 158.00 mg of a hydroxypropyl methylcellulose, 35 mg of a cross-linked acrylic acid based polymer, 3.5 mg of anhydrous colloidal silica and 3.50 mg of magnesium stearate.
4 . A pharmaceutical composition in the form of a tablet comprising 500 mg of Levetiracetam, 187.75 mg of a hydroxypropyl methylcellulose, 7 mg of a polyethylene glycol (PEG), 3.5 mg of an anhydrous colloidal silica and 1.75 mg of magnesium stearate.
5 . A pharmaceutical composition according to any of claims 1 to 4 which is coated with a polyvinyl alcohol.
6 . Use of a pharmaceutical composition according to any of claims 1 to 5 for the treatment of epilepsy.